Beijing Aosaikang Pharmaceutical (002755.SZ): Innovative Drug Liotinib Included in National Reimbursement Drug List

Stock News12-08

Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) announced that its product Liotinib Tablets (brand name: Aoyixin®) has been included in the National Reimbursement Drug List (NRDL) for 2025, as per the notice jointly issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security on December 7, 2025.

Liotinib is a third-generation EGFR TKI with independent intellectual property rights, a novel molecular entity, and significant oral activity. It was jointly developed by the Shanghai Institute of Materia Medica (Chinese Academy of Sciences), the Guangzhou Institutes of Biomedicine and Health (Chinese Academy of Sciences), and Jiangsu Aosaikang Pharmaceutical Co., Ltd. The drug is indicated for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC).

The inclusion of Liotinib Tablets in the NRDL is expected to enhance the drug's accessibility, facilitate market expansion, and positively impact its sales performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175177403?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 08:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175177403","market":"sg","top_or_hot":-1,"title":"Beijing Aosaikang Pharmaceutical (002755.SZ): Innovative Drug Liotinib Included in National Reimbursement Drug List","media":"Stock News","content":"<p>Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) announced that its product Liotinib Tablets (brand name: Aoyixin®) has been included in the National Reimbursement Drug List (NRDL) for 2025, as per the notice jointly issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security on December 7, 2025.</p>\n<p>Liotinib is a third-generation EGFR TKI with independent intellectual property rights, a novel molecular entity, and significant oral activity. It was jointly developed by the Shanghai Institute of Materia Medica (Chinese Academy of Sciences), the Guangzhou Institutes of Biomedicine and Health (Chinese Academy of Sciences), and Jiangsu Aosaikang Pharmaceutical Co., Ltd. The drug is indicated for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC).</p>\n<p>The inclusion of Liotinib Tablets in the NRDL is expected to enhance the drug's accessibility, facilitate market expansion, and positively impact its sales performance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Aosaikang Pharmaceutical (002755.SZ): Innovative Drug Liotinib Included in National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Aosaikang Pharmaceutical (002755.SZ): Innovative Drug Liotinib Included in National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 08:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) announced that its product Liotinib Tablets (brand name: Aoyixin®) has been included in the National Reimbursement Drug List (NRDL) for 2025, as per the notice jointly issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security on December 7, 2025.</p>\n<p>Liotinib is a third-generation EGFR TKI with independent intellectual property rights, a novel molecular entity, and significant oral activity. It was jointly developed by the Shanghai Institute of Materia Medica (Chinese Academy of Sciences), the Guangzhou Institutes of Biomedicine and Health (Chinese Academy of Sciences), and Jiangsu Aosaikang Pharmaceutical Co., Ltd. The drug is indicated for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC).</p>\n<p>The inclusion of Liotinib Tablets in the NRDL is expected to enhance the drug's accessibility, facilitate market expansion, and positively impact its sales performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1175177403","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175177403","pubTimestamp":1765152622,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) announced that its product Liotinib Tablets (brand name: Aoyixin®) has been included in the National Reimbursement Drug List (NRDL) for 2025, as...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BK1574":"生物医药B类股","BK1161":"生物科技","BK0028":"国家队","BK0239":"医药制造","002755":"奥赛康","06978":"永泰生物-B"},"translate_title":"北京奥赛康药业（002755.SZ）：创新药碘替尼纳入国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"002755":1},"content_text":"Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) announced that its product Liotinib Tablets (brand name: Aoyixin®) has been included in the National Reimbursement Drug List (NRDL) for 2025, as per the notice jointly issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security on December 7, 2025.\nLiotinib is a third-generation EGFR TKI with independent intellectual property rights, a novel molecular entity, and significant oral activity. It was jointly developed by the Shanghai Institute of Materia Medica (Chinese Academy of Sciences), the Guangzhou Institutes of Biomedicine and Health (Chinese Academy of Sciences), and Jiangsu Aosaikang Pharmaceutical Co., Ltd. The drug is indicated for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC).\nThe inclusion of Liotinib Tablets in the NRDL is expected to enhance the drug's accessibility, facilitate market expansion, and positively impact its sales performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175177403","isCrawlerRequest":true}